This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
SAB Biotherapeutics Inc
Drug Names(s): SAB 301, SAB301
SAB-301 is a polyclonal antibody therapeutic providing passive immunization against MERS-CoV. SAB-301 is produced utilizing the DiversitAb platform which leverages transchromosomic cattle (Tc Bovine) to produce fully human polyclonal antibodies in cows. The platform produces the entire repertoire of human antibodies similar to human response.
SAB-301 was produced by immunizing cattle with a clade B spike protein nanoparticle vaccine (Al-Hasa strain). The polyclonal antibody therapeutic was then purified from plasma.
SAB-301 (MERS-CoV) News
Additional information available to subscribers only: